Untitled

Abstract

Autologous Stem Cell Transplantation (ASCT) is the main stay of care in relapsed lymphomas including diffuse large B-cell lymphoma (DLBCL). There are different conditioning regimens which differ in efficacy and toxicity. Carmustine, etoposide, ARA-C, melphalan (BEAM), lomustine, etoposide, ARA-C, melphalan (LEAM) and lomustine, ARA-C, cyclophosphamide, etoposide (LACE) are commonly used condition in regimes. Therefore a less toxic regimen might improve the results in relapsed lymphoma patients.